Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by ADEL K EL-NAGGAR and YOSHITSUGU MITANI.
ADEL K EL-NAGGAR
Connection Strength
5.537
YOSHITSUGU MITANI
  1. Reciprocal and Autonomous Glucocorticoid and Androgen Receptor Activation in Salivary Duct Carcinoma. Clin Cancer Res. 2020 03 01; 26(5):1175-1184.
    View in: PubMed
    Score: 0.737
  2. Novel MYBL1 Gene Rearrangements with Recurrent MYBL1-NFIB Fusions in Salivary Adenoid Cystic Carcinomas Lacking t(6;9) Translocations. Clin Cancer Res. 2016 Feb 01; 22(3):725-33.
    View in: PubMed
    Score: 0.559
  3. Alterations associated with androgen receptor gene activation in salivary duct carcinoma of both sexes: potential therapeutic ramifications. Clin Cancer Res. 2014 Dec 15; 20(24):6570-81.
    View in: PubMed
    Score: 0.517
  4. MicroRNA profiling of salivary adenoid cystic carcinoma: association of miR-17-92 upregulation with poor outcome. PLoS One. 2013; 8(6):e66778.
    View in: PubMed
    Score: 0.472
  5. Novel chromosomal rearrangements and break points at the t(6;9) in salivary adenoid cystic carcinoma: association with MYB-NFIB chimeric fusion, MYB expression, and clinical outcome. Clin Cancer Res. 2011 Nov 15; 17(22):7003-14.
    View in: PubMed
    Score: 0.419
  6. Expression and regulation of the ?N and TAp63 isoforms in salivary gland tumorigenesis clinical and experimental findings. Am J Pathol. 2011 Jul; 179(1):391-9.
    View in: PubMed
    Score: 0.407
  7. Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic carcinoma: Incidence, variability, and clinicopathologic significance. Clin Cancer Res. 2010 Oct 01; 16(19):4722-31.
    View in: PubMed
    Score: 0.387
  8. Correction: Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets. Clin Cancer Res. 2023 Jul 14; 29(14):2737.
    View in: PubMed
    Score: 0.237
  9. Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma. J Clin Oncol. 2023 05 20; 41(15):2843-2851.
    View in: PubMed
    Score: 0.231
  10. Whole-Genome Sequencing of Common Salivary Gland Carcinomas: Subtype-Restricted and Shared Genetic Alterations. Clin Cancer Res. 2021 07 15; 27(14):3960-3969.
    View in: PubMed
    Score: 0.204
  11. Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets. Clin Cancer Res. 2021 02 01; 27(3):852-864.
    View in: PubMed
    Score: 0.197
  12. Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy. Cancer. 2018 09 15; 124(18):3693-3705.
    View in: PubMed
    Score: 0.170
  13. Frequent and differential mutations of the CYLD gene in basal cell salivary neoplasms: linkage to tumor development and progression. Mod Pathol. 2018 07; 31(7):1064-1072.
    View in: PubMed
    Score: 0.163
  14. Spatio-Temporal Genomic Heterogeneity, Phylogeny, and Metastatic Evolution in Salivary Adenoid Cystic Carcinoma. J Natl Cancer Inst. 2017 10 01; 109(10).
    View in: PubMed
    Score: 0.159
  15. Detailed genome-wide SNP analysis of major salivary carcinomas localizes subtype-specific chromosome sites and oncogenes of potential clinical significance. Am J Pathol. 2013 Jun; 182(6):2048-57.
    View in: PubMed
    Score: 0.116
  16. Analysis of B7-H4 Expression Across Salivary Gland Carcinomas Reveals Adenoid Cystic Carcinoma-Specific Prognostic Relevance. Mod Pathol. 2024 Jan; 37(1):100371.
    View in: PubMed
    Score: 0.060
  17. Spatial Immunoprofiling of Adenoid Cystic Carcinoma Reveals B7-H4 Is a Therapeutic Target for Aggressive Tumors. Clin Cancer Res. 2023 08 15; 29(16):3162-3171.
    View in: PubMed
    Score: 0.060
  18. Comprehensive molecular characterization of adenoid cystic carcinoma reveals tumor suppressors as novel drivers and prognostic biomarkers. J Pathol. 2023 11; 261(3):256-268.
    View in: PubMed
    Score: 0.060
  19. Rearrangements, Expression, and Clinical Significance of MYB and MYBL1 in Adenoid Cystic Carcinoma: A Multi-Institutional Study. Cancers (Basel). 2022 Jul 28; 14(15).
    View in: PubMed
    Score: 0.055
  20. LMW cyclin E and its novel catalytic partner CDK5 are therapeutic targets and prognostic biomarkers in salivary gland cancers. Oncogenesis. 2021 May 14; 10(5):40.
    View in: PubMed
    Score: 0.051
  21. Oncogenic Orphan Nuclear Receptor NR4A3 Interacts and Cooperates with MYB in Acinic Cell Carcinoma. Cancers (Basel). 2020 Aug 27; 12(9).
    View in: PubMed
    Score: 0.049
  22. N-Terminal Truncated Myb with New Transcriptional Activity Produced Through Use of an Alternative MYB Promoter in Salivary Gland Adenoid Cystic Carcinoma. Cancers (Basel). 2019 Dec 21; 12(1).
    View in: PubMed
    Score: 0.046
  23. Transcriptomes define distinct subgroups of salivary gland adenoid cystic carcinoma with different driver mutations and outcomes. Oncotarget. 2018 Jan 26; 9(7):7341-7358.
    View in: PubMed
    Score: 0.040
  24. Chromosomal abnormalities and molecular landscape of metastasizing mucinous salivary adenocarcinoma. Oral Oncol. 2017 03; 66:38-45.
    View in: PubMed
    Score: 0.038
  25. Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors. J Clin Oncol. 2017 Jan 20; 35(3):352-360.
    View in: PubMed
    Score: 0.037
  26. A unifying gene signature for adenoid cystic cancer identifies parallel MYB-dependent and MYB-independent therapeutic targets. Oncotarget. 2014 Dec 30; 5(24):12528-42.
    View in: PubMed
    Score: 0.033
  27. Whole exome sequencing of adenoid cystic carcinoma. J Clin Invest. 2013 Jul; 123(7):2965-8.
    View in: PubMed
    Score: 0.029
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.